SEARCH:   Advanced

Blood, 15 June 2008, Vol. 111, No. 12, pp. 5654-5662. Prepublished online as a Blood First Edition Paper on February 27, 2008; DOI 10.1182/blood-2007-11-126003. This Article Full Text Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2007-11-126003v1 111/12/5654    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hassane, D. C. Articles by Jordan, C. T. Search for Related Content PubMed PubMed Citation Articles by Hassane, D. C. Articles by Jordan, C. T. Related Collections Hematopoiesis and Stem Cells Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data Duane C. Hassane1,*, Monica L. Guzman1,*, Cheryl Corbett1, Xiaojie Li1, Ramzi Abboud1, Fay Young1, Jane L. Liesveld1, Martin Carroll2, and Craig T. Jordan1 1 James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY; and 2 Division of Hematology/Oncology, University of Pennsylvania, Philadelphia Increasing evidence indicates that malignant stem cells are important for the pathogenesis of acute myelogenous leukemia (AML) and represent a reservoir of cells that drive the development of AML and relapse. Therefore, new treatment regimens are necessary to prevent relapse and improve therapeutic outcomes. Previous studies have shown that the sesquiterpene lactone, parthenolide (PTL), ablates bulk, progenitor, and stem AML cells while causing no appreciable toxicity to normal hematopoietic cells. Thus, PTL must evoke cellular responses capable of mediating AML selective cell death. Given recent advances in chemical genomics such as gene expression-based high-throughput screening (GE-HTS) and the Connectivity Map, we hypothesized that the gene expression signature resulting from treatment of primary AML with PTL could be used to search for similar signatures in publicly available gene expression profiles deposited into the Gene Expression Omnibus (GEO). We therefore devised a broad in silico screen of the GEO database using the PTL gene expression signature as a template and discovered 2 new agents, celastrol and 4-hydroxy-2-nonenal, that effectively eradicate AML at the bulk, progenitor, and stem cell level. These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Targeting LSCs: powering an old tool Simona Salati, Ruth M. Risueno, and Mickie Bhatia Blood 2008 111: 5423-5424. [Full Text] [PDF] This article has been cited by other articles: J. E. Dick Stem cell concepts renew cancer research Blood, December 15, 2008; 112(13): 4793 - 4807. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020